Praecis Puts Brakes On Plenaxis, Explores Strategic Financing Options
This article was originally published in The Pink Sheet Daily
Executive Summary
Company will record $7.5 mil. in charges after announcing it will not enter a licensing or sale transaction for the prostate cancer therapy.